Stoke Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview

Stoke Therapeutics

01/03/2024 14:04

* Stoke Therapeutics Inc  STOK.OQ   STOK.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 4
(estimated) for the period ending December 31 2023
    * The Bedford Massachusetts-based  company is expected to
report a
0.6% decrease in revenue to $3.25 million from $3.27 million a
year ago, according to the mean estimate from 8 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Stoke Therapeutics Inc
is for
a loss of 63 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $18.00​, above​ its last closing price
of $7.74. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.64       -0.63      -0.55     Beat    12.4
 Jun. 30 2023  -0.62       -0.64      -0.69     Missed  -8.4
 Mar. 31 2023  -0.68       -0.70      -0.53     Beat    23.9​
 Dec. 31 2022  -0.70       -0.70      -0.65     Beat    7.4
 ​​Sep.        -0.68       -0.68      -0.66     Beat    3.5
 30 2022                                                
 Jun. 30 2022  -0.69       -0.69      -0.63     Beat    8.4​
 Mar. 31 2022  0.37        0.36       -0.66     Missed  -282.2
 Dec. 31 2021  -0.64       -0.62      -0.66     Missed  -5.9
 This summary was machine generated March 1 at 14:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)